NewcelX Ltd.
NCEL
Get informed when a big investor buys or sells
+ FollowMarket Cap$919.6K
Close$
Share Statistics
| Market cap | $919,601.00 |
|---|---|
| Enterprise Value | $-2,152,775.00 |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -303.93% |
|---|---|
| Return on Assets | -201.97% |
| Return on Invested Capital | -347.25% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.22 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 18, 2026
EPS Estimate
$-0.53
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
$-0.65
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About NLS Pharmaceutics Ltd
4 employees
CEO: Ronen Twito NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage pharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system d...